Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

GSK and LTZ Therapeutics, an immunotherapy-focused biotechnology company based in Redwood City, CA, will collaborate to advance the development of novel myeloid cell engagers.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Freenome, an early cancer detection company, and Roche announced a collaboration agreement to commercialize Freenome’s cancer screening technology in international markets.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, a biotechnology company developing next-generation T cell receptor-based therapies in oncology, announced that they have entered into a collaboration and license agreement to advance a novel in vivo approach to cell therapy for the treatment of solid tumors.

November 14, 2025

Vol.51 No.42

In Brief

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement

YOU MAY BE INTERESTED IN

GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology

Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S.

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Renew today!

Subscriber content

Never miss an issue!

Login